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ABSTRACT
Objective: The objective of this study was to assess the predictive value of serum level of interleukin 31 (IL31) in diagnosis of osteoporosis (OP) in 
postmenopausal women.
Methods: This case–control study was conducted on 80 individuals, 50 of them with postmenopausal OP diagnosed using dual X-ray absorptiometry 
study, and the other 30 were healthy postmenopausal female controls. Serum level of IL31 was measured using enzyme-linked immunosorbent assay 
technique in both groups.
Results: The mean age of patients was 65.3±4.8 years and controls was 61.1±3.9 years. Mean serum IL31 level was significantly higher among 
postmenopausal patients with OP compared to healthy controls (83.5±34.2 vs. 34.9±7.3ng/ml, p<0.05). The optimum cutoff value of serum IL31 that 
can differentiate between patients with OP in postmenopausal women from controls was >44.51 ng/ml with perfect positive predictive value (PPV) 
(100%), very high accuracy of 92.5%, 88% sensitivity, 100% specificity, and negative predictive value (NPV) 83.3%.
Conclusions: Serum IL31 level was significantly higher in postmenopausal osteoporotic women compared to healthy controls. It was a valid measure 
with high accuracy and perfect PPV and specificity, high sensitivity, and NPV. It can be used to confirm the diagnosis of OP in postmenopausal women.
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INTRODUCTION
Osteoporosis (OP) is a disease characterized by low bone mass and 
microarchitectures destruction of bone tissue, leading to bone fragility 
and increased risk of fracture [1]. Postmenopausal OP is a common bone 
disorder in postmenopausal women and is caused primarily by estrogen 
deficiency resulting from menopause [2]. Due to its prevalence worldwide, 
OP is considered a serious public health concern [3]. In Iraq, the prevalence 
of OP in Iraqi postmenopausal women is 22.8% [4]. The underlying 
mechanism of OP is an imbalance between bone resorption and bone 
formation [5]. Interestingly, immune cells, mainly activated T-lymphocytes 
and antigen-presenting cells, can also express RANKL, therefore, influencing 
bone remodeling, both directly and through cytokine production [6]. For 
example, interleukin (IL)-6, IL-17, tumor necrosis factor-α, and interferon-γ 
promote bone loss by favoring osteoclast production and inhibiting 
osteoblast differentiation [7,8]. Other cytokines, such as IL-4, IL-12, and 
IL-33, are strong suppressors of osteoclast differentiation and inhibit bone 
loss [9,10]. In addition, many of these cytokines have pleiotropic functions 
and their role in bone remodeling is cell type and concentration dependent 
and also influenced by the variable cytokine network involved in different 
physiological and pathological conditions [11].
Local production of eicosanoids and IL is thought to participate in 
the regulation of bone turnover, and excess or reduced production of 
these mediators may underlie the development of OP [11]. This study 
was conducted to assess serum level of IL 31 in postmenopausal 
osteoporotic patient and healthy control and to determine optimal 
cutoff value for IL31 to differentiate between study groups.
METHODS
Study design
This case–control study was conducted at the Rheumatology 
Consultation Clinic of Baghdad Teaching Hospital/Medical City from 
July 2016 to November 2016. Ethical permission to conduct the research 
was obtained from rheumatology unit/department of medicine and a 
signed consent was taken from each participant.
Participants
A total of 50 Iraqi postmenopausal female’s patients with OP diagnosed by 
dual X-ray absorptiometry (DXA) spine and DXA hip which was diagnosed 
by rheumatologist according to the current criteria of the World Health 
Organization [12]. Females ages ranged from 55 to 76 years. Another 30 
healthy volunteer female’s subjects were taken as controls. They have no 
OP by DXA study and non-significant medical history.
Data collection
Full history was taken and complete clinical examination was done 
for all participants in the study. Data collected included age, weight, 
height, body mass index (BMI), smoking status, and the recent relevant 
investigations were recorded inform of C-reactive protein and erythrocyte 
sedimentation rate. None of the studied participants had pathologies 
causing secondary OP or took drugs that could affect bone metabolism.
Measurements
4 ml of venous blood sample was obtained from each subject and 
collected in a non-heparinized plain tube, then centrifuged at 1800× g 
for 10 min to separate serum. The obtained serum labeled and stored 
at −20°C until use, no preservative was added. IL31 was detected 
by enzyme-linked immunosorbent assay technique at immunology 
department/teaching laboratories.
Statistical analysis
Statistical analysis was done using the Statistical Package for the Social 
Sciences version 20 IMB. Anderson–Darling normality test was used 
to test the distribution of variables by a Minitab version 17 software. 
Continuous variables were reported as mean ± standard deviation 
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when normally distributed. Categorical variables were presented as 
numbers and percentages. Difference between normally distributed 
continuous variables was done using independent t-test (Student’s 
test). Difference between categorical variables was measured using 
Chi-square test. The optimum cutoff value of serum IL31 was calculated 
using receiver operating curve with its validity parameters (sensitivity, 
specificity, accuracy, positive predictive value [PPV], and negative 
predictive value). p<0.05 was considered statistically significant.
RESULTS
The mean age of patients was 65.3±4.8 years and for controls 
was 61.1±3.9 years (p<0.001). Mean BMI for patients was 
29.9±4.1 kg/m2 and for controls was 28.9±2.7 kg/m2 (p=0.180). Other 
baseline characteristics are shown in Table 1.
The mean serum IL31 was significantly higher in postmenopausal 
woman compared to healthy controls (83.5±34.2 vs. 34.9±7.3, p<0.001) 
as shown in Fig. 1.
Serum IL31 was excellent test to differentiate between postmenopausal 
women with OP and healthy controls (area under the curve [AUC]=0.93, 
95 confidence interval [CI]=0.85–0.975, p<0.001). Furthermore, at the 
optimum cutoff value >44.51 ng/L, s. IL31 showed highest accuracy of 
92.5% with perfect PPV and specificity of 100% and high sensitivity 
of 88% and NPP of 83.3%. This indicates that the test is excellent test 
to predict woman with postmenopausal OP and confirm the Dx with 
100% as shown in Fig. 2.
DISCUSSION
OP and associated fractures are an important cause of mortality 
and morbidity [13]. Early diagnosis and treatment can reduce 
postmenopausal fracture risk and its complications [14].
This study assessed the predictive value of s. IL31 in diagnosis of OP in 
postmenopausal woman. It showed that serum IL31 was excellent test 
to differentiate between postmenopausal women with OP and healthy 
controls with high accuracy and perfect PPV and specificity and high 
sensitivity and NPP. This is clinically important and may indicate that 
the test is excellent test to predict woman with postmenopausal OP 
and confirm the diagnosis with 100%. The possible explanation of high 
serum IL-31 that we found in the postmenopausal osteoporotic patients 
might be related to the increased release of this cytokine by senescence 
inflammatory immune cells, and this could, therefore, contribute to 
the development of full-blown OP. The elevated IL-31 expression could 
enhance bone resorption through the induction of chemokines and 
pro-inflammatory osteoclastogenic cytokines, which subsequently lead 
to the recruitment of osteoclast precursors from the bone marrow, their 
differentiation, and activation [15].
The current study showed that the mean serum IL31 was significantly 
higher in postmenopausal woman with OP compared to healthy controls 
(83.5±34.2 vs. 34.9±7.3, p<0.001). Moreover, serum IL31 was a valid test 
to differentiate between postmenopausal women with OP and healthy 
controls (AUC=0.93, 95 CI=0.85–0.975, p<0.001). Furthermore, at the 
optimum cutoff value >44.51 ng/L, serum IL31 showed highest accuracy 
of 92.5% with perfect PPV and specificity of 100% and high sensitivity 
of 88% and NPP of 83.3%. Similar finding reported by Ginaldi et al. [15] 
who demonstrated the increase of IL-31 serum levels in postmenopausal 
women with decreased bone mineral density. However, the current study 
reported for the 1st time the predictive diagnostic validity parameters of 
serum IL31 in postmenopausal women with OP.
Several other studies showed that IL-31 stimulated secretion of pro-
inflammatory osteoclastogenic cytokines, chemokines, and matrix 
metalloproteinases, all of which are implicated in differentiation, 
recruitment, and function of osteoclasts and are, therefore, key 
mediators of bone remodeling during aging [16-20].
The main limitation of this study is the small number of patients and 
controls and short duration of the study. Furthermore, we did not 
evaluate the severity of OP and whether serum IL31 correlates with it. 
This can be solved by a larger study size and longer duration. In spite 
of that, this study was the first study that evaluated validity of serum 
IL31 in diagnosis of OP in postmenopausal Iraqi women with strong 
inclusion and exclusion criteria.
CONCLUSION
Serum level of IL31 was significantly higher in patients with 
postmenopausal OP compared to healthy controls and was excellent 
valid test to predict OP in postmenopausal women with high accuracy 
and perfect PPV and specificity and high sensitivity and NPP. This 
suggests that serum IL31 might be used for early diagnosis and 
prevention of OP and subsequent better treatment.
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Table 1: Clinical and anthropometric characteristics in the study group
Variables Controls=30 Osteoporotic=50 p value
Age years, mean±SD 61.1±3.9 65.3±4.8 <0.001 (Significant)
BMI Kg/m2, mean±SD 28.9±2.7 29.9±4.1 0.180
Smoking status, n (%) 6 (20.0%) 24 (48.0%) 0.012 (Significant)
ESR mm, mean±SD 14.1±6.7 21.6±8.0 <0.001 (Significant)
Positive CRP, n (%) 3 (10%) 14 (28%) 0.057
SD: Standard deviation, n: Number, BMI: Body mass index, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein
Fig. 1: Serum interleukin-31 in patients with osteoporosis and 
controls
505
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 503-505
 Abid et al. 
CONFLICTS OF INTEREST
All the authors hereby declare that there are no conflicts of interest.
REFERENCES
1. Hendrijantini N, Alie R, Setiawati R, Astuti ER, Wardhana MP. 
Correlation of bone mineral density (BMD), body mass index (BMI) 
and osteocalcin in postmenopausal women. Biol Med (Aligarh) 2016;8. 
DOI: 10.4172/0974-8369.
2. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev 
Pathol 2011;6:121-45.
3. Reginster JY, Burlet N. Osteoporosis: A still increasing prevalence. 
Bone 2006;38:S4-9.
4. Gorial FI, Abuaese ND, Hnasaeen NH. Prevalence and associated 
factors of osteoporosis in post-menopausal Iraqi women: A cross 
sectional two centers study. Int J Mod Biol Med 2013;3:41-9.
5. Wu S, Liu Y, Zhang L, Han Y, Lin Y, Deng HW, et al. Genome-
wide approaches for identifying genetic risk factors for osteoporosis. 
Genome Med 2013;5:44.
6. Weitzmann MN, Pacifici R. T cells: Unexpected players in the bone 
loss induced by estrogen deficiency and in basal bone homeostasis. Ann 
N Y Acad Sci 2007;1116:360-75.
7. McLean RR. Proinflammatory cytokines and osteoporosis. Curr 
Osteoporos Rep 2009;7:134-9.
8. David JP, Schett G. TNF and bone. Curr Dir Autoimmun 2010;11:135-44.
9. Fujii T, Kitaura H, Kimura K, Hakami ZW, Takano-Yamamoto T. IL-4 
inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL 
expression in TNF-α-activated stromal cells and direct inhibition 
of TNF-α-activated osteoclast precursors via a T-cell-independent 
mechanism in vivo. Bone 2012;51:771-80.
10. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, et al. 
Interleukin-33, a target of parathyroid hormone and oncostatin m, 
increases osteoblastic matrix mineral deposition and inhibits osteoclast 
formation in vitro. Endocrinology 2011;152:1911-22.
11. Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of 
pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb) 
2013;23:43-63.
12. WHO Scientific Group on the Assessment of Osteoporosis at Primary 
Health Care Level, Summary Meeting Report. Geneva, Switzerland: 
World Health Organization; 2004. Available from: http://www.who.int/
chp/topics/Osteoporosis.pdf .
13. Kumar AV, Joseph AK, Gokul G, Alex MP, Naveena G. Clinical outcome 
of calcium, Vitamin D3 and physiotherapy in osteoporotic population in 
the Nilgiris district. Int J Pharm Pharm Sci 2016;8:157-60.
14. MiraÇi M, Demeti A, Ylli Z, KelliÇi S, Tarifa D. The cost-effectiveness 
of ibandronate and alendronate for the treatment of osteoporosis in a 
specialized clinic in Tirana. Int J Pharm Pharm Sci 2015;7:207-11.
15. Ginaldi L, De Martinis M, Ciccarelli F, Saitta S, Imbesi S, Mannucci C, 
et al. Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC 
Immunol 2015;16:60.
16. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological 
functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 
2008;19:347-56.
17. Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, 
et al. IL-31 a cytokine involved in immunity and inflammation. Int J 
Immunopathol Pharm 2010;23:709-13.
18. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-
inflammatory cytokines in human monocytes and macrophages 
following stimulation with staphylococcal exotoxins. Allergy 
2010;65:712-21.
19. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by 
IL-31 and functional consequences. Eur J Cell Biol 2012;91:552-66.
20. Lencel P, Magne D. Inflammaging: The driving force in osteoporosis? 
Med Hypotheses 2011;76:317-21.
Fig. 2: Receiver operating characteristic test for serum 
interleukin 31 as a test to differentiate between postmenopausal 
women with osteoporosis and controls
